1. Home
  2. ARDX vs MAX Comparison

ARDX vs MAX Comparison

Compare ARDX & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

N/A

Current Price

$3.02

Market Cap

797.8M

Sector

Health Care

ML Signal

N/A

Logo MediaAlpha Inc.

MAX

MediaAlpha Inc.

N/A

Current Price

$14.92

Market Cap

657.4M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
ARDX
MAX
Founded
2007
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
797.8M
657.4M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
ARDX
MAX
Price
$3.02
$14.92
Analyst Decision
Strong Buy
Buy
Analyst Count
11
8
Target Price
$12.80
★ $15.71
AVG Volume (30 Days)
★ 4.3M
1.0M
Earning Date
11-03-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 25.81
EPS
N/A
★ 1.32
Revenue
$2,607,000.00
★ $1,113,600,000.00
Revenue This Year
$19.21
$21.30
Revenue Next Year
$28.19
$11.16
P/E Ratio
★ N/A
$11.03
Revenue Growth
N/A
★ 28.78
52 Week Low
$2.96
$7.09
52 Week High
$8.40
$14.87

Technical Indicators

Market Signals
Indicator
ARDX
MAX
Relative Strength Index (RSI) 37.18 76.72
Support Level N/A $8.01
Resistance Level $3.35 N/A
Average True Range (ATR) 0.13 0.69
MACD 0.01 0.42
Stochastic Oscillator 15.19 96.34

Price Performance

Historical Comparison
ARDX
MAX

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

About MAX MediaAlpha Inc.

MediaAlpha Inc provides a platform that enables insurance carriers and distributors to target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It serves as a customer acquisition channel in property and casualty insurance, health insurance, and life insurance. The company operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.

Share on Social Networks: